The objective of the innovation project is to develop and clinically validate the first diagnostic device for the early detection of diabetic neuropathy (also referred to as diabetic foot). NQT was measured on the dorsum of the foot in 160 healthy subjects as well as 60 and 128 diabetic patients without and with DSP, respectively. This condition is the main cause of death in children with diabetes and can cause long-term problems. RESULTS—Sural nerve amplitude potentials measured by the point-of-care device shared very strong correlation with the reference standard (Spearman’s correlation coefficient 0.95, P < 0.001). “Oh, I’ll do that a little later, I just want to relax right now,” I said, putting on my sunglasses and lying back on the cushioned row of seats in the back of the tiny boat. The device provides patients with a simple, fast, accurate and cost-effective way to be screened for sight-threatening diabetic retinopathy without having to leave their primary care office. But now perhaps it is time to give it another try now with the combination of pump and glucose sensor in the MiniMed Duo. The breakthrough feature is this: it prevents any type of discomfort and painful pricking of the finger to check glucose levels. With so many exciting new devices in the future, diabetes care and management could become easier. ERG photopic implicit times were prolonged in both diabetic and glaucoma patients: 2 tailed t-test: Control mean 33.2 msec vs DM mean 34.6 msec, implicit time p=0.045; Control mean 33.2 msec vs G mean 35.4 msec, implicit time p=0.0009. Currently, diabetics either use glucometers and administer doses when necessary via injections, or utilize insulin pumps that constantly monitor glucose levels and automatically deliver insulin as needed (a closed-loop feature). Oh, and the news release says the Duo would include an "improved adhesive pad (that) accommodates movement without compromising adhesion" -- which could be a big advantage in itself! Indeed, the research behind it could significantly impact the success of other combined, single-site devices being developed by competitors -- including Insulet, which is working with a still-unnamed partner to create an all-in-one OmniPod-CGM device. The results of a pilot clinical study, carried out at the Leeds Institute of Cardiovascular and Metabolic Medicine under the supervision of Professor Peter Grant, suggest that the new monitor has the potential to perform as well as conventional technologies.
While this product is certainly a dramatic breakthrough and will undoubtedly significantly improve diabetes management, it still requires a port on the outside of the body for the insulin reserve to be topped up. Medtronic is pretty familiar at being “first” when it comes to new diabetes devices. If you recall, Medtronic brought us the first-ever insulin pump in 2003 that wirelessly connected with a glucose meter; an integrated CGM-insulin pump device in 2006; and in 2009 introduced Low Glucose Suspend technology overseas (followed by Low Threshold Suspend here in the States in September 2013). Aside from this Minimed Duo, most of the attention’s been on completing their next-gen system known as the Minimed 640G, a predictive Low Threshold Suspend device able to shut off insulin in advance, whenever it predicts the onset of a low blood sugar. The company says it plans to launch that predictive device by year’s end in Europe, and some even believe they may get FDA approval for the U.S. sometime in 2015 (!) And that next-gen pump is rumored to have a completely different design than the “pager-look” we’ve become accustomed to seeing from Medtronic, so that’s exciting too! At a local diabetes conference I attended recently in Indianapolis, Medtronic’s Chief Medical Officer Dr.
Labstyle Innovations Corp. There was mention of the predictive technology, along with a nice explanation of how all of this is part of the larger Artificial Pancreas goal. It seems a good time to push the envelope on these kind of diabetes devices given the FDA’s new accelerated pathway on medical devices, aimed at quickening the pace of innovation. Hopefully the AP tech, which the FDA has now defined and includes the Minimed 530G system because of its ability to automatically suspend insulin delivery, falls under that umbrella. Short of bringing the new Minimed Duo and other new products to the States, it’s very exciting to see Medtronic rolling out this novel technology that certainly is influencing the rest of the diabetes device industry and brings us more options to help manage our diabetes. Of course, with this year’s ADA Scientific Sessions now less than 10 days away, we can’t wait to see and hear what may be showcased under the “yet to be approved” glass displays on the Expo floor in San Francisco… stay tuned for that!
This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. We could keep people safe and dramatically reduce the risk of complications,” said Russell. For more information about Healthline’s partnership with Diabetes Mine, please click here.